

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

PE/Cyanine7 anti-human CD11b

RRID:AB_2734451

Type: Antibody

Proper Citation

BioLegend Cat# 393104, RRID:AB_2734451

Antibody Information

URL: http://antibodyregistry.org/AB_2734451

Proper Citation: BioLegend Cat# 393104, RRID:AB_2734451

Target Antigen: CD11b

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD11b

Description: This monoclonal targets CD11b

Target Organism: human

Clone ID: Clone LM2

Antibody ID: AB_2734451

Vendor: BioLegend

Catalog Number: 393104

Alternative Catalog Numbers: 393103

Record Creation Time: 20250820T032735+0000

Record Last Update: 20250820T161839+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD11b.

No alerts have been found for PE/Cyanine7 anti-human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Zheng C, et al. (2024) IFN γ -induced BST2⁺ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. *Cell reports*, 43(4), 114088.

Bailey C, et al. (2023) Genetic and pharmaceutical targeting of HIF1 α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. *Cell reports. Medicine*, 4(11), 101236.